Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders
Andrew R. Branagan(Massachusetts General Hospital), Madhav V. Dhodapkar(Yale Cancer Center), Chandra Sekhar Boddupall(Yale Cancer Center), Dennis Cooper(Yale Cancer Center), Lin Zhang(Chinese University of Hong Kong), Rakesh Verma(Harvard University), Thomas Ferencz(Yale Cancer Center), Stuart Seropian(Yale Cancer Center), Terri L. Parker(Yale Cancer Center), Eamon Duffy(Auckland City Hospital), Xiaopan Yao(Dana-Farber Cancer Institute), Randy A. Albrecht(Icahn School of Medicine at Mount Sinai)
Cited by 1
Related Papers
Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis
|Journal of Infection|2020|1.2k
Anthracycline Dose Intensification in Acute Myeloid Leukemia
|New England Journal of Medicine|2009|907
Animal models for COVID-19
|Nature|2020|877